BIOA Earnings & Financial Statements
BioAge Labs, Inc.
$5.42
-$0.15(-2.69%)
33
Overall
60
Value
9
Tech
31
Quality
Market Cap
$248.76M
Volume
614.84K
52W Range
$5.04 - $25.96
Target Price
$35.63
BIOA earnings and financial statements: BioAge Labs, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BIOA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $8.99M | - | - | - |
| Operating income | -$92.78M | -$78.19M | -$48.40M | -$39.97M |
| EBITDA | -$79.69M | -$68.58M | -$35.72M | -$39.35M |
| Net income | -$80.61M | -$71.11M | -$43.67M | -$39.72M |
| EPS (diluted) | $-2.24 | $-6.63 | $-38.17 | $-23.76 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $294.89M | $358.23M | $25.92M | $28.43M |
| Total liabilities | $22.84M | $35.11M | $66.60M | $8.27M |
| Shareholders’ equity | $272.05M | $323.13M | -$40.67M | $20.16M |
| Cash and equivalents | $188.89M | $354.35M | $21.64M | $27.64M |
| Long-term debt | $2.33M | $2.50M | $8.20M | $2.25M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$81.63M | -$51.52M | -$37.36M | -$36.18M |
| Capital expenditure | -$719.0K | -$366.0K | - | - |
| Free cash flow | -$82.35M | -$51.89M | -$37.53M | -$36.28M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BIOA | $5.42 | -2.7% | 614.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |